PPAR gamma as a metabolic regulator: insights from genomics and pharmacology
- PMID: 15673477
- DOI: 10.1017/S1462399405008793
PPAR gamma as a metabolic regulator: insights from genomics and pharmacology
Abstract
Since its identification in the early 1990 s, peroxisome-proliferator-activated receptor gamma (PPAR gamma), a nuclear hormone receptor, has attracted tremendous scientific and clinical interest. The role of PPAR gamma in macronutrient metabolism has received particular attention, for three main reasons: first, it is the target of the thiazolidinediones (TZDs), a novel class of insulin sensitisers widely used to treat type 2 diabetes; second, it plays a central role in adipogenesis; and third, it appears to be primarily involved in regulating lipid metabolism with predominantly secondary effects on carbohydrate metabolism, a notion in keeping with the currently in vogue 'lipocentric' view of diabetes. This review summarises in vitro studies suggesting that PPAR gamma is a master regulator of adipogenesis, and then considers in vivo findings from use of PPAR gamma agonists, knockout studies in mice and analysis of human PPAR gamma mutations/polymorphisms.
Similar articles
-
Peroxisome proliferator-activated receptor gamma and the regulation of adipocyte function: lessons from human genetic studies.Best Pract Res Clin Endocrinol Metab. 2005 Dec;19(4):501-23. doi: 10.1016/j.beem.2005.10.001. Best Pract Res Clin Endocrinol Metab. 2005. PMID: 16311214 Review.
-
Structure and physiological functions of the human peroxisome proliferator-activated receptor gamma.Arch Immunol Ther Exp (Warsz). 2008 Sep-Oct;56(5):331-45. doi: 10.1007/s00005-008-0037-y. Arch Immunol Ther Exp (Warsz). 2008. PMID: 18836859 Review.
-
Peroxisome proliferator-activated receptor-gamma-mediated effects in the vasculature.Circ Res. 2008 Feb 15;102(3):283-94. doi: 10.1161/CIRCRESAHA.107.164384. Circ Res. 2008. PMID: 18276926 Review.
-
Effects of PPAR gamma agonists on cardiovascular function in obese, non-diabetic patients.Vascul Pharmacol. 2006 Jul;45(1):29-35. doi: 10.1016/j.vph.2005.11.013. Epub 2006 Jun 14. Vascul Pharmacol. 2006. PMID: 16777491 Review.
-
PPAR-gamma receptor agonists--a review of their role in diabetic management in Trinidad and Tobago.Mol Cell Biochem. 2004 Aug;263(1-2):189-210. Mol Cell Biochem. 2004. PMID: 15524180 Review.
Cited by
-
The angiotensin receptor blocker and PPAR-γ agonist, telmisartan, delays inactivation of voltage-gated sodium channel in rat heart: novel mechanism of drug action.Pflugers Arch. 2012 Dec;464(6):631-43. doi: 10.1007/s00424-012-1170-3. Epub 2012 Oct 17. Pflugers Arch. 2012. PMID: 23073892
-
Cinnamic Acid Ameliorates Nonalcoholic Fatty Liver Disease by Suppressing Hepatic Lipogenesis and Promoting Fatty Acid Oxidation.Evid Based Complement Alternat Med. 2021 Sep 2;2021:9561613. doi: 10.1155/2021/9561613. eCollection 2021. Evid Based Complement Alternat Med. 2021. PMID: 34512784 Free PMC article.
-
Targeting Lipid Peroxidation for Cancer Treatment.Molecules. 2020 Nov 5;25(21):5144. doi: 10.3390/molecules25215144. Molecules. 2020. PMID: 33167334 Free PMC article. Review.
-
Association between the peroxisome proliferator-activated receptor gamma Pro12Ala variant and haplotype and pancreatic cancer in a high-risk cohort of smokers: a pilot study.Pancreas. 2009 Aug;38(6):631-7. doi: 10.1097/MPA.0b013e3181a53ef9. Pancreas. 2009. PMID: 19436234 Free PMC article.
-
Body mass index and obesity- and diabetes-associated genotypes and risk for pancreatic cancer.Cancer Epidemiol Biomarkers Prev. 2011 May;20(5):779-92. doi: 10.1158/1055-9965.EPI-10-0845. Epub 2011 Feb 25. Cancer Epidemiol Biomarkers Prev. 2011. PMID: 21357378 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources